Cytotoxics will be a key growth opportunity for third-party manufacturers as biopharma increases its injectables outsourcing over the next few years, an industry report has predicted.
After patent expiration led to facility shuttering and cutbacks, Irish manufacturing will receive a $130m (€100m) boost to prepare for Pfizer’s new pipeline, the company says.
Critical Pharmaceuticals says its protein and peptide delivery technologies offer long acting injectables and greater compliance, saving money and easing patient administration.
Lonza has launched a service to help biopharmas decide if promising protein drug candidates are worth developing, from an immunogenicity and manufacturing standpoint.
Catalent says customers are applying controlled release technology to transform drugs into better treatments across all stages of development as it expands its Kentucky manufacturing site.
BD says its new quality by design glass prefillable syringe offers added safety in delivering biologics as the industry continues to shift toward biotechnology.
The Japanese joint venture between Dr. Reddy’s and Fujifilm has been called-off though both say future collaboration remains likely, especially in API production.
Boehringer Ingelheim will build a biomanufacturing facility in Shanghai in a strategic alliance designed to cater for Pharmas nervous about setting up plants in China.
Hepregen has agreed to provide US CRO QPS Holdings with long-term liver cell models to aid its offerings in drug metabolism and pharmacokinetic (DMPK) services.
In-Pharmatechnologist.com presents its latest round-up of the movers and shakers in the world of pharmaceuticals, including news from the MHRA, Achillion and Halozyme.
Although preclinical work for CROs has fallen flat in recent quarters, Covance is looking to take advantage of the industry’s shift to early biologic developments and lead optimization.
Regulators and the drug industry met in Moscow last week to develop a framework for firms developing biologics and biosimilars in the Russian Federation.
Outsourcing-Pharma.com presents its latest round-up of the movers and shakers in the pharma service industry, including news from Theorem and Symbiosis.
Evotec says it is confident underlying growth, expansion of its clinical stage pipeline and upcoming milestone payments will counter Q1’s downcast results.
Melding metals to APIs could make drugs easier to deliver according to Sweden's Recipharm which partnered to add a new chemistry to its offering last week.
DKSH has upgraded its cold chain infrastructure in Southeast Asia as both small and large manufacturers increase their access needs to emerging markets.
CRO PPD (Pharmaceutical Product Development) is bolstering its bioassay and bioanalytical services in both the US and Brazil, respectively, in preparation for more niche biologic and biosimilar developments.
Pennsylvania-based Calvert Laboratories and Particle Sciences are combining their expertise in preclinical drug development to provide clients with more streamlined options.
Drug solubility science, technology and solutions will take centre stage at “The Bioavailability Challenge” a free to attend online event in-Pharmatechnologist.com is hosting on Wednesday, March 20.
A new partnership between a niche cancer drug discovery company and biotech powerhouse Celgene could pave the way for the future of cancer drug discovery and delivery.
Pantarhei Bioscience has sold in Estetra, its oral contraceptive development JV, to partner Uteron Pharma and will use the proceeds to fund further development.
Quintiles painted a rosy picture of the CRO sector in its much anticipated IPO, predicting that biopharma R&D spending will increase and demand for outsourced research will grow.
in-Pharmatechnologist.com presents a roundup of news in the fine chemicals sector, beginning with Johnson Matthey which has started a review of its active pharmaceutical ingredient (API) business after competition in the UK impacted its third quarter...
Outsourcing-Pharma.com presents its latest round-up of the movers and shakers in the pharma service industry, including news from Recipharm, Aesica and SMS Oncology.
With Angiomax potentially going generic in 2015, The Medicines Company has collaborated with Alnylam over a 'pragmatic' high cholesterol drug to aid future growth.
Highly sought-after guidance on quality agreements for contract manufacturing organizations (CMOs) and biosimilar developers is expected in 2013, according to a list of future guidance documents released by the US Food and Drug Administration (FDA).
GE Healthcare says new cell science lab in Wales will save drugmakers time and money and create more accurate alternatives to animal-based drug toxicity testing models.
India's national Atomic Energy Regulation Board (AERB) has approved GVK Biosciences to perform certain isotope-labeling research in its facility, according to the Hyderabad-based contract research organization (CRO).
Menarini has committed millions of euros to an antibody drug conjugate (ADC) clinical development and manufacturing pact with Oxford BioTerapeutics (OBT).
US biosecurity experts are calling on industry and the Government to “get a handle” on the supply chain for drugs used in times of pandemic or bio attack.
Outsourcing-Pharma.com presents the low down on new services forged by partnerships and M&A (mergers and acquisitions), including a molecular biology offering for Quotient, Onyx’s added purification and separation capabilities, and Accenture’s new...
